Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 30, 2016

Study Completion Date

January 28, 2017

Conditions
Cushing Disease
Interventions
DRUG

Pasireotide 0.6 MG/ML

The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).

All Listed Sponsors
lead

University of Palermo

OTHER

NCT03080181 - Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment | Biotech Hunter | Biotech Hunter